Does the media prefer ARWR or IDYA?

In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 13 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of -0.04 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AXSM or IDYA?

In the previous week, Axsome Therapeutics had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 14 mentions for Axsome Therapeutics and 13 mentions for IDEAYA Biosciences. Axsome Therapeutics' average media sentiment score of 0.59 beat IDEAYA Biosciences' score of -0.04 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ABVX or IDYA more profitable?

Abivax has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% IDEAYA Biosciences -75.93% -16.73% -15.34%

Does the media prefer ABVX or IDYA?

In the previous week, IDEAYA Biosciences had 12 more articles in the media than Abivax. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 1 mentions for Abivax. Abivax's average media sentiment score of 1.23 beat IDEAYA Biosciences' score of -0.04 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KRYS or IDYA?

In the previous week, Krystal Biotech had 10 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 23 mentions for Krystal Biotech and 13 mentions for IDEAYA Biosciences. Krystal Biotech's average media sentiment score of 0.90 beat IDEAYA Biosciences' score of -0.04 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IDYA or SMMT?

In the previous week, IDEAYA Biosciences had 7 more articles in the media than Summit Therapeutics. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 6 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.80 beat IDEAYA Biosciences' score of -0.04 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IDEAYA Biosciences (IDYA) Competitors

$37.02 +0.78 (+2.15%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$37.52 +0.49 (+1.34%)

As of 08/7/2026 07:34 PM Eastern

Compare

IDYA vs. ARWR, AXSM, ABVX, KRYS, and SMMT

Should you buy IDEAYA Biosciences stock or one of its competitors? MarketBeat compares IDEAYA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IDEAYA Biosciences include Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), Abivax (ABVX), Krystal Biotech (KRYS), and Summit Therapeutics (SMMT).

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Arrowhead Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$669.50M	18.44	-$1.63M	-$2.25	N/A
IDEAYA Biosciences	$218.71M	14.87	-$113.70M	-$1.94	N/A

In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 13 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of -0.04 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
IDEAYA Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Arrowhead Pharmaceuticals currently has a consensus price target of $97.33, suggesting a potential upside of 11.05%. IDEAYA Biosciences has a consensus price target of $50.13, suggesting a potential upside of 35.40%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

Summary

IDEAYA Biosciences beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Axsome Therapeutics has a net margin of -26.59% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

IDEAYA Biosciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.15	-$183.17M	-$3.73	N/A
IDEAYA Biosciences	$218.71M	14.87	-$113.70M	-$1.94	N/A

In the previous week, Axsome Therapeutics had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 14 mentions for Axsome Therapeutics and 13 mentions for IDEAYA Biosciences. Axsome Therapeutics' average media sentiment score of 0.59 beat IDEAYA Biosciences' score of -0.04 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics presently has a consensus target price of $265.55, suggesting a potential upside of 24.82%. IDEAYA Biosciences has a consensus target price of $50.13, suggesting a potential upside of 35.40%. Given IDEAYA Biosciences' higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Axsome Therapeutics beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Abivax?

Abivax (NASDAQ:ABVX) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Abivax currently has a consensus price target of $156.50, indicating a potential upside of 19.53%. IDEAYA Biosciences has a consensus price target of $50.13, indicating a potential upside of 35.40%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

IDEAYA Biosciences has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
IDEAYA Biosciences	$218.71M	14.87	-$113.70M	-$1.94	N/A

Abivax has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Abivax has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

In the previous week, IDEAYA Biosciences had 12 more articles in the media than Abivax. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 1 mentions for Abivax. Abivax's average media sentiment score of 1.23 beat IDEAYA Biosciences' score of -0.04 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IDEAYA Biosciences beats Abivax on 12 of the 15 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Krystal Biotech has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.83	$204.83M	$7.98	40.91
IDEAYA Biosciences	$218.71M	14.87	-$113.70M	-$1.94	N/A

Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to IDEAYA Biosciences' net margin of -75.93%. Krystal Biotech's return on equity of 19.34% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Krystal Biotech presently has a consensus price target of $361.56, suggesting a potential upside of 10.75%. IDEAYA Biosciences has a consensus price target of $50.13, suggesting a potential upside of 35.40%. Given IDEAYA Biosciences' higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

In the previous week, Krystal Biotech had 10 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 23 mentions for Krystal Biotech and 13 mentions for IDEAYA Biosciences. Krystal Biotech's average media sentiment score of 0.90 beat IDEAYA Biosciences' score of -0.04 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Krystal Biotech beats IDEAYA Biosciences on 14 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Summit Therapeutics?

IDEAYA Biosciences (NASDAQ:IDYA) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

IDEAYA Biosciences currently has a consensus target price of $50.13, suggesting a potential upside of 35.40%. Summit Therapeutics has a consensus target price of $26.15, suggesting a potential upside of 87.35%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Summit Therapeutics has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Summit Therapeutics	N/A	-168.94%	-141.92%

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, IDEAYA Biosciences had 7 more articles in the media than Summit Therapeutics. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 6 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.80 beat IDEAYA Biosciences' score of -0.04 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than Summit Therapeutics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.87	-$113.70M	-$1.94	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

IDEAYA Biosciences beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.25B	$3.69B	$7.03B	$13.01B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-19.08	9.02	270.57	25.03
Price / Sales	14.87	1,294.50	599.50	86.03
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	3.17	17.61	11.21	6.43
Net Income	-$113.70M	-$13.25M	$3.45B	$348.10M
7 Day Performance	4.28%	6.24%	4.67%	4.41%
1 Month Performance	-0.70%	-3.50%	-1.28%	-1.11%
1 Year Performance	60.26%	61.28%	77.33%	23.99%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	3.4887 of 5 stars	$37.02 +2.2%	$50.13 +35.4%	+60.3%	$3.25B	$218.71M	N/A	80	News Coverage Earnings Report Upcoming Earnings Analyst Forecast
ARWR Arrowhead Pharmaceuticals	1.6496 of 5 stars	$86.22 +0.5%	$95.08 +10.3%	+433.8%	$12.08B	$829.45M	N/A	400	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
AXSM Axsome Therapeutics	3.6523 of 5 stars	$227.42 -2.9%	$261.48 +15.0%	+103.0%	$12.05B	$638.50M	N/A	380	Upcoming Earnings Insider Trade
ABVX Abivax	3.2252 of 5 stars	$118.84 -4.3%	$156.50 +31.7%	+86.7%	$10.84B	N/A	N/A	61	Positive News
KRYS Krystal Biotech	3.9726 of 5 stars	$363.28 -0.3%	$360.67 -0.7%	+135.4%	$10.74B	$389.13M	48.57	210	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. ARWR, AXSM, ABVX, KRYS, and SMMT

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does IDEAYA Biosciences compare to Axsome Therapeutics?

Summary

How does IDEAYA Biosciences compare to Abivax?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Summary

How does IDEAYA Biosciences compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. ARWR, AXSM, ABVX, KRYS, and SMMT

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Which has stronger earnings and valuation, ARWR or IDYA?

Does the media prefer ARWR or IDYA?

Do insiders & institutionals have more ownership in ARWR or IDYA?

Is ARWR or IDYA more profitable?

Do analysts prefer ARWR or IDYA?

Which has more risk & volatility, ARWR or IDYA?

Summary

How does IDEAYA Biosciences compare to Axsome Therapeutics?

Is AXSM or IDYA more profitable?

Do insiders and institutionals have more ownership in AXSM or IDYA?

Which has more volatility & risk, AXSM or IDYA?

Which has better valuation and earnings, AXSM or IDYA?

Does the media prefer AXSM or IDYA?

Do analysts prefer AXSM or IDYA?

Summary

How does IDEAYA Biosciences compare to Abivax?

Do institutionals & insiders hold more shares of ABVX or IDYA?

Do analysts prefer ABVX or IDYA?

Which has higher valuation & earnings, ABVX or IDYA?

Is ABVX or IDYA more profitable?

Which has more risk and volatility, ABVX or IDYA?

Does the media prefer ABVX or IDYA?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Which has higher valuation and earnings, KRYS or IDYA?

Which has more volatility & risk, KRYS or IDYA?

Is KRYS or IDYA more profitable?

Do analysts prefer KRYS or IDYA?

Does the media refer more to KRYS or IDYA?

Do insiders and institutionals hold more shares of KRYS or IDYA?

Summary

How does IDEAYA Biosciences compare to Summit Therapeutics?

Do analysts recommend IDYA or SMMT?

Is IDYA or SMMT more profitable?

Do insiders & institutionals have more ownership in IDYA or SMMT?

Does the media refer more to IDYA or SMMT?

Which has more risk & volatility, IDYA or SMMT?

Which has preferable earnings and valuation, IDYA or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools